Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
about
Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combinationCircular RNAs in heart failure.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.Sacubitril-valsartan: novel therapy for heart failure.Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.Angiotensin Receptor-Neprilysin Inhibition.Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.Insights into implementation of sacubitril/valsartan into clinical practice.Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.Publishing in a heart failure journal-where lies the scientific interest?Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.[Acute and chronic heart failure].[The new ESC Guidelines for acute and chronic heart failure 2016].Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.October 2016 at a glance: treatment of heart failure.Sacubitril/Valsartan (LCZ696) in Heart Failure
P2860
Q37597972-9EA9B5D3-9ECD-4CD7-B6B5-3C6541036DFAQ38739402-CF80A599-6665-4DAE-8175-372507BF7665Q39192295-A38A6E98-4038-4730-908E-9289491B1F0AQ41148299-5F4F3E1A-0EAB-49F5-B14E-26DE4122CA48Q46132135-B4864064-44E9-4094-8FB8-33A488A8ACF1Q46770238-4A3C9F72-FB8C-4CC4-B9AD-236415F82200Q47700110-F1DA7F83-CB87-49FA-A11C-B23AA8613951Q49586918-5DA5BE60-8C9E-4D7D-89B3-AE467E1C7335Q49718855-A9B45277-2F99-4FDC-B90F-AEA56CF02786Q49848555-305AFFCC-1882-40C5-8AA9-9A4CCCE8C5B4Q50048824-CD0D1BDC-9F5A-445F-9C04-2CF4B5D9CA42Q50660284-47BD1D6E-2592-46C6-988E-81AF3E8E2FF3Q52675558-190BAC82-2FB2-40DC-B01E-8547A5CC333FQ52821448-D07E01F4-3DC8-49E1-8A8D-CF6061D4E574Q52844963-226D26DC-5EA0-4E1C-BA6C-A41D6D67C059Q53121367-D1509075-3022-42C2-9AD8-1FAD51D50B25Q54575009-4853E084-6949-4079-BCF1-32B891B8AA04Q57396137-3A5E4AF7-6AB0-41B5-8FC3-D2588F525AB3
P2860
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@en
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@nl
type
label
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@en
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@nl
prefLabel
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@en
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@nl
P2093
P2860
P356
P1476
Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.
@en
P2093
Akshay S Desai
Brian Claggett
Jean Rouleau
John R Teerlink
Karl Swedberg
Martin Lefkowitz
Milton Packer
Orly Vardeny
Prospective Comparison of ARNI ...... re (PARADIGM-HF) Investigators
Scott D Solomon
P2860
P304
P356
10.1002/EJHF.580
P577
2016-06-10T00:00:00Z